EDUCATIONAL COURSE:
Preclinical and early-phase clinical pharmacology

6th February 2019

PAMM
40th EORTC-PAMM WINTER MEETING
6th - 9th February 2019
Verona, Italy

40th EORTC-PAMM Winter Meeting
7th – 9th February 2019

Palazzo della Gran Guardia,
piazza Bra, Verona – Italy

PROGRAMME

PAMM Board

Eric Raymond, France, Chair
Elisa Giovannetti, The Netherlands
Annette Larsen, France
Godefridus J. Peters, The Netherlands

Scientific Committee

Andrea Bonetti, Italy
Etienne Chateleut, France
Joseph Ciccolini, France
Elisa Giovannetti, The Netherlands
Monika Hegi, Switzerland
Georg Hempel, Germany
Markus Joerger, Switzerland
Annette Larsen, France
Roberto Leone, Italy

Brian Leyland-Jones, USA
Paola Perego, Italy
Godefridus J. Peters, The Netherlands
Roger M. Phillips, UK
Eric Raymond, France
Christian Rolfo, Belgium
Andrzej Skladanowski, Poland
Andrew D. Westwell, UK
Nadia Zaffaroni, Italy
Local Organizing Committee

Andrea Bonetti
Department of Oncology
Mater Salutis Hospital Legnago
Verona, Italy

Roberto Leone
Department of Diagnostic and Public Health, Section of Pharmacology,
University of Verona, Italy

Sponsorship and Cooperation

In cooperation with
ESO Recommended Event
EDUCATIONAL COURSE: PRECLINICAL AND EARLY-PHASE CLINICAL PHARMACOLOGY

Chairs: Paola Perego, Italy and Godefridus J. Peters, The Netherlands

9.00-9.25 How to perform pharmacological studies in vitro
Paola Perego, Molecular Pharmacology Unit, Istituto Nazionale dei Tumori Milano, Italy

9.25-9.50 To combine or not to combine: drug interactions and tools for their analysis
Godefridus J. Peters, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

9.50-10.15 Realistic preclinical approaches: hypoxia and 3D models
Roger Phillips, School of Applied Sciences, University of Huddersfield, UK

10.15-10.30 Continuous Coffee Break

10.30-10.55 How to navigate among the OMICS data and their correlation with pharmacological data
Giovanni Cirriello, Dept. Computational Biology, University of Lausanne, Switzerland

10.55-11.20 Drug development, after the NCI-compounds initiative
Hans Hendriks, Hendriks Pharmaceutical Consulting, Purmerend, The Netherlands

11.20-11.45 Neighborhood matters: new tools and practical approaches for co-culturing cancer cells
Elisa Giovannetti, Amsterdam University Medical Center, VU University, The Netherlands

11.45-12.45 Practical session on data analysis and technical aspects

12.45-13.45 Free Time for Lunch

13.45-14.45 Practical session on OMICS data

14.45-15.00 Introduction to pharmacometrics
Georg Hempel, Institut für Pharmazeutische und Medizinische Chemie, - Klinische Pharmazie, Westfälische Wilhelms-Universität Münster, Germany

15.00-15.25 Pharmacometrics with immunotherapy
Joseph Ciccolini, Pharmacokinetics Laboratory, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, France

15.25-15.50 PK, PD, first dose and schedule selection in phase I
Eric Raymond, Oncologie Médicale, Centre Hospitalier Paris Saint-Joseph, France

15.50-16.05 Final discussion with Q&A

19.00 EORTC-PAMM WINTER MEETING, WELCOME COCKTAIL
THURSDAY 7TH FEBRUARY

SESSION I: THE MODERN LANDSCAPE AND NEW AVENUES IN THE TREATMENT OF MALIGNANCIES
Chairs: Erik Raymond, France and Nadia Zaffaroni, Italy

8.30-9.00  Inhibitors of deubiquitinases: from preclinical to clinical studies
Stig Linder, Karolinska Institute, Linköping University, Sweden

9.00-9.30  Host-microbe co-metabolism and cancer drug efficacy
Filibre Cabreiro, Birkbeck University of London, United Kingdom

9.30-10.00 The role of the microbiome in immunotherapy
Lisa Derosa, Institut Gustave Roussy, France

10.00-10.30 Metabolic hallmarks of tumor and immune cells in the tumor microenvironment.
Marina Kreutz, University of Regensburg, Germany

10.30-11.00 Next generation histopathological diagnosis: from omics to clinical applications
Aldo Scarpa, University of Verona, Italy

11.00-11.30 Does the dose of monoclonal antibody make matter?
Etienne Chatelut, University of Toulouse, France

11.30-12.00 Is pharmacometrics the missing link of immunotherapy?
Joseph Ciccolini, University of Marseille, France

12.00-12.30 The immune suppressive myeloid environment in cancers
Vincenzo Bronte, University of Verona, Italy

12.30-13.00 Lunch, poster viewing

SESSION II: GASTRO-INTESTINAL CANCERS
Chairs: Annette Larsen, France and Alfredo Guglielmi, Italy

14.00-14.30 Introductory remarks
Elizabeth Smyth, Cambridge University Hospital NHS Foundation Trust, UK

14.30-15.00 TAK-ing aim at chemoresistance: the role of TGF beta pathway as therapeutic target in digestive tumors
Davide Melisi, University of Verona, Italy

15.00-15.30 TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression
Adam Frampton, Imperial College of London, UK

15.30-16.00 The new ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up of gastrointestinal stromal tumours
Iwona Lugowska, MSCMI, Warsaw, Poland

16.00-16.30 Coffee break, poster viewing

16.30-17.00 New therapeutic opportunities from DNA damage repair to immunotherapy in pancreatic cancer
Giampaolo Tortora, Catholic University of Rome, Italy

17.00-17.30 Surgery as adjuvant treatment in pancreatic cancer?
Claudio Bassi, University of Verona, Italy

SATELLITE SYMPOSIUM SERVIER (NO ECM)
Chairs: Godefridus J. Peters, The Netherlands and Andrea Bonetti, Italy

17.30-18.15 Present and future of trifluridine/tipiracil
Mario Scartozzi, University of Cagliari, Italy

18.15-18.45 Presentation of three clinical cases
Alessandra Auriemma, Michele Pavarana, Jacopo Giuliani, Italy

18.45-19.00 Discussion and closure
FRIDAY 8TH FEBRUARY

SESSION III: New Challenges in Drug Resistance Mechanisms
Chairs: Etienne Chatelut, France and Paola Perego, Italy

8.30-9.00  
Synthetic viability – mechanisms of drug resistance in BRCA1/2-deficient mouse mammary tumors  
Sven Rottenberg, University of Bern, Switzerland

9.00-9.30  
Evolution and characterization of carboplatin resistance at single cell resolution  
Oliver Harismendy – UCSD, La Jolla, CA, USA

9.30-10.00  
Oncogenic signaling pathways in the Cancer Genome Atlas  
Giovanni Ciriello, University of Lausanne, Switzerland

10.00-10.30  
Coffee break, poster viewing

SESSION IV: Oral Communications 1
Chairs: Etienne Chatelut, France and Paola Perego, Italy

10.30-10.45  
The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab  
Jacopo Giuliani, Mater Salutis Hospital, Legnago, Italy

10.45-11.00  
New paradigms in the treatment of advanced renal cell carcinoma  
Camillo Porta, Fondazione Maugeri, Pavia, Italy

11.00-11.15  
Analysis of predictive biomarkers in novel patient-derived xenograft (PDX) models of peritoneal metastasis from colorectal cancer (pmCRC)  
Wolfgang Walther, University of Berlin, Germany

11.15-11.30  
Pharmacological and next-generation sequencing studies unravel multifactorial resistance to the novel antimetabolite RX-3117 in non-small cell lung cancer cells  
Btissame El Hassouni, Amsterdam University Medical Center, VU University, The Netherlands

11.30-11.45  
Extracellular vesicles: subcellular organelles with the potential to spread cancer resistance  
Fanny Ender, University of Luebeck, Germany

11.45-12.00  
Overcoming TRAIL resistance in cancer stem cells: computer-aided design of c-FLIP inhibitors  
Kok Yung Lee, Cardiff University, UK

12.00-12.15  
Inhibition of stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition induced selection of cancer stem cells in BRAF-mutated melanoma  
Maria Elena Pisanu, Istituto Superiore di Sanità, Rome, Italy

LECTURE ECM

12.15-13.00  
Mutational model in oncology: a new paradigm for the future?  
Nello Martini, Presidente Fondazione Ricerca e Salute, Italy

13.00-14.00  
Lunch, poster viewing
FRIDAY 8\textsuperscript{TH} FEBRUARY

SESSION V: THORACIC CANCERS
Chairs: Alberto Amadori, Italy and Michele Milella, Italy

14.00-14.30  \textbf{Introductory remarks}
Benjamin Besse, Gustave Roussy Cancer Campus, Paris, France

14.30-15.00  \textbf{Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives}
Emilio Bria, Catholic University of Rome, Italy

15.00-15.30  \textbf{Splicing modulation as novel therapeutic strategy against diffuse malignant pleural and peritoneal mesothelioma}
Elisa Giovannetti, Amsterdam University Medical Center, VU University, The Netherlands

15.30-16.00  \textit{Coffee break, poster viewing}

SESSION VI: ORAL COMMUNICATIONS 2
Chairs: Alberto Amadori, Italy and Michele Milella, Italy

16.00-16.15  \textbf{Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer, through reduced expression of SDHC}
Gro Vatne Røsland, Haukeland University Hospital, Bergen, Norway

16.15-16.30  \textbf{Cytidine deaminase (CDA): a double-faced Janus in hematology oncology}
Mélanie Donnette, Aix Marseille University, France

16.30-16.45  \textbf{Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line}
Alessandro Leonetti, Amsterdam University Medical Center, VU University, The Netherlands

16.45-17.00  \textbf{Population pharmacokinetic modelling of etoposide in Ewing sarcoma patients}
Farina Hellmann, University of Münster, Germany

17.00-17.15  \textbf{Pemetrexed treatment induces PD-L1 upregulation in NSCLC cell lines}
Andrea Cavazzoni, University of Parma, Italy

17.15-17.30  \textbf{Development of ruthenium(II)-arene complexes as anticancer agents}
Sandra Aranđelović, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

LECTURE ECM

17.30-18.00  \textbf{Cancer in movies and literature}
Luciano Defiore, Sapienza University, Rome, Italy

18.00  \textbf{PAMM MEETING NO ECM}

20.30  \textbf{Social Dinner}
### SESSION VII: BREAST CANCER
Chairs: Franco Muggia, USA and Stefania Gori, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8.30-9.00 | **Introductory remarks**  
Etienne Brain, Institut Curie, Hopital Rene Huguenin, Paris, France |
| 9.00-9.30 | **Closing the gap between precision biology and personalized cancer medicine:**  
Pierfranco Conte, Istituto Oncologico Veneto and University of Padua, Italy |
| 9.30-10.00 | **Multi-gene testing: from tissue to liquid biopsy in breast cancer**  
Gabriele Zoppoli, University of Genova, Italy |
| 10.00-10.15 | **Optimizing CDK 4/6 inhibitors in breast cancer**  
Andrea Bonetti, Mater Salutis Hospital, Legnago, Italy |
| 10.15-10.30 | **Coffee break, poster viewing**                                      |

### SESSION VIII: HAEMATOLOGICAL MALIGNANCES
Chairs: Giovanni Martinelli and Fabio Benedetti, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10.30-11.00 | **Current advancements and future challenges in paediatric haematology oncology**  
Simone Cesaro, University Hospital of Verona, Italy |
| 11.00-11.30 | **Targeting bone marrow stromal support to haematological malignancies**  
Mauro Krampera, University of Verona, Italy |
| 11.30-12.00 | **Pharmacometric considerations in the treatment of leukaemia in children**  
Georg Hempel, University of Münster, Germany |

### THE BURGER-KELLAND LECTURE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12.00-12.45 | **From targeted therapy to targeted therapy**  
Godefridus J. Peters, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands |

### 12.45 POSTER PRIZE AND CLOSURE
POSTER PRESENTATIONS

Please note that the numbers listed correspond to the numbers of the poster boards

P.01  Interrogating the phosphoproteome for the selection of target candidates and (non-toxic) drug combinations in pancreatic ductal adenocarcinoma
Vallés MA, Amsterdam University Medical Center, VU University, The Netherlands

P.02  MicroRNAs as predictive biomarkers for response to systemic treatment in patients with pancreatic ductal adenocarcinoma
Boyd LNC, VUmc, Cancer Center Amsterdam, Department of Surgery, The Netherlands

P.03  MiR-21 as prognostic biomarker in radically resected cholangiocarcinomas
Garajová I, University Hospital of Parma, Italy

P.04  Attacking from all fronts: a comprehensive study of primary and secondary brain tumors focusing on the identification of therapeutic targets and the development of non-invasive diagnostic methods
Vieito Villar M, Vall d’Hebron Institute of Oncology, Spain

P.05  AXL downstream targeting unravels synergistic drug combinations in ovarian carcinoma cells
Corno C, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

P.06  Molecular mechanisms of AXL mediated drug resistance in NSCLC
Engelsen A, Dept. Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Norway

P.07  Biomechanical properties of PDAC affect key microRNAs expression and chemoresistance
Capula M, VUmc Cancer Center Amsterdam, Leiden University, The Netherlands

P.08  Consensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi process
Siebel C, University Children's Hospital Muenster, Germany

P.09  Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors
Giuliani J, Mater Salutis Hospital, Legnago, Italy

P.10  First-line therapy for metastatic non-small cell lung cancer: integrating clinical benefit with the cost of drugs
Giuliani J, Mater Salutis Hospital, Legnago, Italy

P.11  Grade >=3 neutropenia and clinical outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil
Giuliani J, Mater Salutis Hospital, Legnago, Italy
Survival outcomes in metastatic colorectal cancer patients treated with panitumumab: the role of primary tumor side
Giuliani J, Mater Salutis Hospital, Legnago, Italy

Biological evaluation of new 1,2,4-oxadiazole topsentin analogs as anticancer agents
Parrino B, Dept. STEBICEF, University of Palermo, Italy

Preclinical activity of new imidazo [2,1-b][1,3,4] thiazoles derivatives on pancreatic cancer cells
Cascioferro S, Dept. STEBICEF, University of Palermo, Italy

Omiics-based regulatory networks for the identification of disease driver pathways in platelets of patients with pancreatic cancer
Mantini G, Amsterdam University Medical Center, VU University, The Netherlands

Novel lactate dehydrogenase-A (LDH-A) inhibitors overcome chemoresistance of mesothelioma mediated by hypoxia
Li Petri G, Amsterdam University Medical Center, VU University, The Netherlands

Preclinical activity of the new nucleoside analogue RX-3117 against pancreatic cancer
Infante J, Amsterdam University Medical Center, VU University, The Netherlands

Simultaneous quantification of asparaginases by capillary zone electrophoresis
Bauch T, Dept. Pharmaceutical and Medical Chemistry – Clinical Pharmacy, University of Muenster, Germany

microRNA signatures in liquid biopsies as biomarkers to predict resistance to targeted therapies in metastatic melanoma
Fattore L, Regina Elena National Cancer Institute, Rome, Italy

The anti-tumor efficacy of palbociclib, a CDK4/6 inhibitor, is enhanced by the combination with chemotherapy in triple negative breast cancer
Cretella D, Dept. of Medicine and Surgery, Lab. of Experimental Oncology, University of Parma, Italy

Why Immunoliposome and not ADC to extend trastuzumab to Her2 negative breast cancer models: a proof of concept study
Rodallec A, SMARTc Unit, Aix-Marseille University, France

Long-lasting (14 years) complete clinical response in an advanced BRCA2 mutation carrier pancreatic cancer patient treated with GEMOX as first line chemotherapy
Greco F, Mater Salutis Hospital, Legnago, Italy
**Platinum Sponsorship**

- **Servier Oncology**
- **Pfizer Oncology**
- **Novartis**

**Gold Sponsorship**

- **Roche**
- **Ipsen**
- **MundiPharma**
- **Bristol-Myers Squibb**
- **Sandoz**

**Silver Sponsorship**

- **AstraZeneca**
- **Bayer**
- **Celgene**
- **MSD**